TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
Brief Summary: The HYGIA study was designed to investigate prospectively

1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects primarily evaluated at primary care settings
2. the impact of changes in ambulatory BP during follow-up in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
3. the influence of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk in hypertensive patients
4. the prevalence of an altered BP profile as a function of antihypertensive treatment, circadian time of treatment, age, and presence of diabetes, among other factors.


Options:
A: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): 1, 2 | Intervention Type: DEVICE; Name: ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
D: Arm Label: Evening medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Medication - | Arm Label: Morning medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Medication - | Intervention Type: DRUG; Name: Anti-hypertensive Medication -; Assigned to Arm(s): Evening medication, Morning medication

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis
Brief Summary: The question whether the sequential diuretic therapy, that means using an antialdosteronic drug at first and adding a loop diuretic in nonresponders, is better than the combination of the two diuretics from the beginning (combined diuretic therapy) in the treatment of ascites in patients with cirrhosis is still open. Therefore, the aim of the study is to compare sequential versus combined diuretic therapy in these patients. One hundred patients will be randomized into two groups. Group A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day. Group B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.

The percentage of responders to dthe diuretic treatment, the time to get the resolution of ascites and the rate of adverse effects will be compared between the two Groups of Patients.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone and furosemide | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone and furosemide | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A, B
B: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intermittent bolus group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3% hypertonic saline | Arm Label: slow continuous infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3% hypertonic saline | Intervention Type: DRUG; Name: 3% hypertonic saline; Assigned to Arm(s): Intermittent bolus group, slow continuous infusion group
D: Arm Label: Tolvaptan, Samsca; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolvaptan or Samsca | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo or sugar pill | Intervention Type: DRUG; Name: Tolvaptan or Samsca; Assigned to Arm(s): Tolvaptan, Samsca | Intervention Type: DRUG; Name: placebo or sugar pill; Assigned to Arm(s): sugar pill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of a Positive Expiratory Pressure (PEP) on Dyspnea and Dynamic Hyperinflation During Exercise in COPD Patients
Brief Summary: From the relationship between pathophysiology of chronic obstructive pulmonary disease (COPD), dyspnea, and dynamic hyperinflation during ventilatory increasing, the investigators hypothesize that

1. Positive expiratory pressure (PEP) breathing will reduce dyspnea more than normal breathing during exercise in mild to moderate COPD patients.
2. PEP breathing will improve dynamic hyperinflation during exercise more than normal breathing in mild to moderate COPD patients.
3. PEP breathing will improve cardiorespiratory function during exercise than normal breathing in mild to moderate COPD patients.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Device: Conical Positive Expiratory Pressure Device (C-PEP) | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Other: Control breathing | Intervention Type: DEVICE; Name: Conical Positive Expiratory Pressure Device (C-PEP); Assigned to Arm(s): I | Intervention Type: OTHER; Name: Control breathing; Assigned to Arm(s): C
B: Arm Label: FT; Type: EXPERIMENTAL; Interventions: Behavioral: Breathlessness Intervention Service (BIS) | Arm Label: WL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best supportive care (Standard care) | Intervention Type: BEHAVIORAL; Name: Breathlessness Intervention Service (BIS); Assigned to Arm(s): FT | Intervention Type: BEHAVIORAL; Name: Best supportive care (Standard care); Assigned to Arm(s): WL
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ventilation feedback, Behavioral: exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ventilation feedback | Intervention Type: BEHAVIORAL; Name: ventilation feedback; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Relaxation Response (instruction, pocket practice card prov), Behavioral: Mindfulness training using model developed from UMass | Intervention Type: BEHAVIORAL; Name: Relaxation Response (instruction, pocket practice card prov); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Mindfulness training using model developed from UMass; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
Brief Summary: Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period/Two-Treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: miglustat | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: miglustat; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Treatment Period 1: LUM/IVA to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Placebo (PBO) to LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Arm Label: Treatment Period 1: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Period 2: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 1: LUM/IVA to LUM/IVA, Treatment Period 1: Placebo (PBO) to LUM/IVA | Intervention Type: DRUG; Name: LUM/IVA; Assigned to Arm(s): Treatment Period 2: LUM/IVA
C: Arm Label: Part A: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Arm Label: Part B: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Intervention Type: DRUG; Name: LUM; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA
D: Intervention Type: DRUG; Name: CPX; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
Brief Summary: Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period/Two-Treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation


Options:
A: Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: miglustat | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: miglustat; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transdermal Electroacupuncture for Opioid Detoxification
Brief Summary: This single-blind, randomized clinical trial tests whether electroacupuncture, provided as an adjunctive treatment, improves outcomes among patients receiving inpatient opioid detoxification from opioids.


Options:
A: Arm Label: Probuphine; Type: EXPERIMENTAL; Interventions: Drug: Probuphine (buprenorphine implant) | Arm Label: placebo implant; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo implant | Arm Label: sublingual buprenorphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine | Intervention Type: DRUG; Name: Probuphine (buprenorphine implant); Assigned to Arm(s): Probuphine | Intervention Type: DRUG; Name: placebo implant; Assigned to Arm(s): placebo implant | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): sublingual buprenorphine
B: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Linkage; Type: EXPERIMENTAL; Interventions: Behavioral: Linkage | Intervention Type: BEHAVIORAL; Name: Linkage; Assigned to Arm(s): Linkage
C: Arm Label: Active electroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroacupuncture | Arm Label: Sham electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Electroacupuncture | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Active electroacupuncture, Sham electroacupuncture
D: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05% In Patients With Actinic Keratoses ON Non-head Locations (REGION-I)
Brief Summary: The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.


Options:
A: Arm Label: PEP005 (Ingenol Mebutate) gel; Type: EXPERIMENTAL; Interventions: Drug: PEP005 (Ingenol Mebutate) gel, 0.015% | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle Gel | Intervention Type: DRUG; Name: PEP005 (Ingenol Mebutate) gel, 0.015%; Assigned to Arm(s): PEP005 (Ingenol Mebutate) gel | Intervention Type: DRUG; Name: Vehicle Gel; Assigned to Arm(s): Vehicle gel
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): 2
C: Arm Label: PEP005 (ingenol mebutate) Gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEP005 (ingenol mebutate) Gel | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 (ingenol mebutate) Gel; Assigned to Arm(s): PEP005 (ingenol mebutate) Gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Vehicle gel
D: Arm Label: PEP005 gel; Type: EXPERIMENTAL; Interventions: Drug: PEP005 Gel | Arm Label: Vehicle gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle gel | Intervention Type: DRUG; Name: PEP005 Gel; Assigned to Arm(s): PEP005 gel | Intervention Type: DRUG; Name: Vehicle gel; Assigned to Arm(s): Vehicle gel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study With Freeze Dried HL10, Three Dosages of 200 mg/kg Ideal Body Weight Versus Standard Therapy in ALI/ARDS Patients
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of three doses of HL 10 given at fixed time intervals compared to standard therapy


Options:
A: Intervention Type: DRUG; Name: HL 10; Assigned to Arm(s): N/A
B: Arm Label: Albuterol Sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Albuterol Sulfate, Procedure: Mini-Bronchoalveolar Lavage (BAL) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Mini-Bronchoalveolar Lavage (BAL), Drug: Placebo | Intervention Type: DRUG; Name: Albuterol Sulfate; Assigned to Arm(s): Albuterol Sulfate | Intervention Type: PROCEDURE; Name: Mini-Bronchoalveolar Lavage (BAL); Assigned to Arm(s): Albuterol Sulfate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mesenchymal stem cell arm; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stem cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mesenchymal stem cells; Assigned to Arm(s): Mesenchymal stem cell arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Assigned to Arm(s): Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIANA - Diabetes Mellitus: Neue Wege Der Optimierung Der allgemeinärztlichen Betreuung
Brief Summary: Patients with type-2 diabetes mellitus have an higher risk developing secondary disorders. In an epidemiological longitudinal study of about 1.150 patients with type 2 diabetes mellitus we investigate determinants and predictors for long-term prognosis. The patients are recruited and supervised in practices of general practitioners of the administrative district of Ludwigsburg/Heilbronn (Baden-Württemberg, Germany). In a subgroup of about 200 patients with a dissatisfactory metabolic status (HbA1c \> 7,5%) a randomised interventional study is performed. The intervention comprises a telephone counseling by the medical secretary of each practice executed in a predefined period of time. The outcome parameters of interest are the change of HbA1c, the development of secondary disorders and adverse events, quality of life and risk factor control, as well as hospitalization and mortality.

The aim of the study was to develop an patient-centred instrument implementable in the routine medical care in order to enhance the prognosis of patients with type-2 diabetes mellitus.


Options:
A: Arm Label: The Education Health Program; Type: EXPERIMENTAL; Interventions: Behavioral: The Education Health Program | Intervention Type: BEHAVIORAL; Name: The Education Health Program; Assigned to Arm(s): The Education Health Program
B: Arm Label: Control-usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention paired testing and remote monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose | Intervention Type: BEHAVIORAL; Name: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose; Assigned to Arm(s): Intervention paired testing and remote monitoring
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Other: Telephone counseling | Intervention Type: OTHER; Name: Telephone counseling; Assigned to Arm(s): Telephone Counseling
D: Arm Label: A, 1, I; Type: EXPERIMENTAL; Interventions: Device: Home blood pressure tele-management system. | Arm Label: A, 2, I; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care. | Intervention Type: DEVICE; Name: Home blood pressure tele-management system.; Assigned to Arm(s): A, 1, I | Intervention Type: OTHER; Name: Usual care.; Assigned to Arm(s): A, 2, I

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Walnut Supplement on Cardio-Metabolic Risk Factors in Patients With Metabolic Syndrome
Brief Summary: The purpose of this study is to determine whether a daily supplement of 30 grams of walnut is effective in the treatment of metabolic syndrome (MetS).


Options:
A: Arm Label: Brazil Nuts; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Brazil Nut | Intervention Type: DIETARY_SUPPLEMENT; Name: Brazil Nut; Assigned to Arm(s): Brazil Nuts
B: Arm Label: Walnut Supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Walnut Supplementation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: No walnut supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Supplementation; Assigned to Arm(s): Walnut Supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: No walnut supplementation; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: healthy life style education | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Behavioral: healthy life style education | Intervention Type: BEHAVIORAL; Name: healthy life style education; Assigned to Arm(s): A, B
D: Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts and peanut butter; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Supplementation With Dual Megadose of Vitamin A in the Post-partum About Vitamin A Levels in Breast Milk, Serum Levels of Vitamin A and Iron in the Binomial Mother-son and Growth and Morbidity of Children Under 6 Months
Brief Summary: The purpose of this study is to evaluate the effect of maternal supplementation with 400,000 IU of oral retinol palmitate in the post-partum, the nutritional situation of the binomial mother-child, on growth and morbidity of children in breastfeeding in the first six months of life.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
D: Arm Label: 0 mg retinol; Type: PLACEBO_COMPARATOR; Interventions: Other: 0 mg retinol activity equivalents | Arm Label: 12 mg BC; Type: EXPERIMENTAL; Interventions: Other: 12 mg of BC | Arm Label: 6 mg of CX; Type: EXPERIMENTAL; Interventions: Other: 6 mg of CX | Arm Label: 1.0 mg RAE; Type: EXPERIMENTAL; Interventions: Other: 1.0 mg RAE | Intervention Type: OTHER; Name: 0 mg retinol activity equivalents; Assigned to Arm(s): 0 mg retinol | Intervention Type: OTHER; Name: 12 mg of BC; Assigned to Arm(s): 12 mg BC | Intervention Type: OTHER; Name: 6 mg of CX; Assigned to Arm(s): 6 mg of CX | Intervention Type: OTHER; Name: 1.0 mg RAE; Assigned to Arm(s): 1.0 mg RAE

Answer: A